Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse(TM) Filler Launch
MWN-AI** Summary
Dr. Benjamin Eskenazi, a renowned plastic surgeon based in Miami Beach, has been appointed as the lead consultant for Evolus, Inc.'s launch of their innovative Evolysse™ filler line. This collaboration marks a significant milestone in the aesthetic industry, as Evolus introduces its first major advancement in hyaluronic acid dermal fillers in over a decade. With Dr. Eskenazi's extensive expertise in facial anatomy and injectable treatments, he will be instrumental in supporting aesthetic providers during the nationwide rollout of these injectable products.
Evolus’ Evolysse™ fillers, recently approved by the FDA, include Evolysse™ Form and Evolysse™ Smooth, employing groundbreaking Cold-X™ technology. This method preserves the natural structure of the hyaluronic acid molecule, resulting in long-lasting and natural-looking results. The partnership emphasizes Evolus' commitment to patient safety and provider education, as Dr. Eskenazi will provide essential guidance and support to practitioners who may have questions or encounter challenges with the new fillers.
Dr. Eskenazi, the founder of Avabello Aesthetics, brings over eight years of private practice experience and has been recognized for his contributions to aesthetic education. His distinguished career includes completing rigorous training at the Cleveland Clinic Foundation, which endowed him with profound knowledge of aesthetic and reconstructive procedures. His oversight ensures high standards of medical expertise in the services provided at Avabello.
The Evolysse™ line, supported by clinical studies demonstrating its safety and efficacy, is set to launch commercially in 2025, with additional products planned for subsequent years. This partnership positions Dr. Eskenazi as a vital resource for aesthetic providers, reinforcing his role in enhancing patient outcomes and promoting excellence in aesthetic medicine.
MWN-AI** Analysis
The recent announcement naming Dr. Benjamin Eskenazi as the lead consultant for Evolus’ highly anticipated Evolysse™ filler launch presents significant market implications for both Evolus, Inc. and the aesthetic medicine sector. As a recognized leader in the field, Dr. Eskenazi’s association lends credibility and expertise that could greatly enhance the success of Evolysse™, a groundbreaking hyaluronic acid technology promising enhanced safety and efficacy.
Evolus (NASDAQ: EOLS) is strategically positioning itself to disrupt the dermal filler market with its innovative Cold-X™ technology, which preserves the natural structure of the hyaluronic acid molecule for longer-lasting, natural-looking results. This technology not only addresses the growing consumer demand for aesthetically pleasing procedures but also aligns with the industry trend towards minimally invasive solutions. Dr. Eskenazi's role in facilitating provider education and patient safety underscores Evolus’ commitment to quality, potentially translating into higher adoption rates among practitioners who are often hesitant about new products.
Investors should pay attention to the expected commercial launch timeline as it may serve as a catalyst for stock performance. With Evolysse™ Form and Evolysse™ Smooth set for release in 2025, and additional products following in subsequent years, Evolus has an opportunity to capture market share, especially in a region like Miami Beach, known for its high demand for aesthetic services. Furthermore, with Dr. Eskenazi’s established reputation and the engaging marketing potential, the collaboration could enhance brand visibility and consumer confidence.
In summary, as Dr. Eskenazi and Evolus embark on this innovative journey, stakeholders should consider monitoring developments closely. This partnership not only reinforces Evolus’ market positioning but also highlights a larger trend within the aesthetic industry towards greater accountability and patient-centric practices.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
Headline Summary: Board-certified plastic surgeon brings extensive expertise in facial anatomy and injectable treatments to support nationwide rollout of breakthrough hyaluronic acid technology. Partnership underscores Evolus' commitment to patient safety and provider education for their new FDA-approved filler line.
MIAMI BEACH, Fla. , Sept. 22, 2025 /PRNewswire/ -- Evolus, Inc. (NASDAQ: EOLS), a leading publicly traded aesthetic beauty company, has named Dr. Benjamin Eskenazi , MD, FACS, founder of Miami Beach's premier Avabello Aesthetics, as lead consultant for the national launch of their revolutionary Evolysse™ filler line . This partnership comes as Evolus introduces the first major technological breakthrough in hyaluronic acid dermal fillers in a decade, with Dr. Eskenazi providing critical expertise to support aesthetic providers nationwide.
As lead consultant, Dr. Eskenazi will leverage his extensive experience in the injectable space and deep knowledge of facial anatomy to assist aesthetic providers should questions arise during treatment with the new Evolysse™ products. While not specifically mandated by the FDA or any regulatory agency, this collaboration showcases Evolus' proactive commitment to patient safety and provider support during the launch of their groundbreaking filler technology.
The FDA recently approved Evolysse™ Form and Evolysse™ Smooth, marking Evolus' entry into the U.S. hyaluronic acid dermal filler market. The revolutionary fillers utilize innovative Cold-X™ technology that preserves the natural structure of the hyaluronic acid molecule for longer-lasting, natural-looking results.
"I'm honored to partner with Evolus in bringing this innovative technology to practitioners across the country," said Dr. Eskenazi. "My role is to provide real-world expertise and guidance to ensure providers feel confident and supported when using these advanced fillers. This collaboration reflects Evolus' genuine commitment to patient safety and demonstrates their dedication to excellence in aesthetic medicine."
Evolus specifically selected Dr. Eskenazi based on his distinguished track record as an aesthetic educator, expert injector, and recognized authority in facial aesthetics. Dr. Eskenazi brings over eight years of private practice experience and completed his plastic surgery training at the world-renowned Cleveland Clinic Foundation, gaining extensive expertise in both aesthetic and reconstructive procedures.
The partnership positions Dr. Eskenazi as a key resource for aesthetic providers nationwide who may encounter questions or challenges during Evolysse™ treatments. His expertise will be available to support the medical community as they integrate this breakthrough technology into their practices.
Avabello stands apart as one of the few medical spas in Miami Beach overseen by a board-certified plastic surgeon, ensuring that every treatment is performed with the highest level of medical expertise. This fundamental understanding of aesthetics brings unparalleled safety and effectiveness to the services offered at the practice.
The Evolysse™ line represents a significant advancement in dermal filler technology, with clinical studies providing compelling evidence around their safety and efficacy. The commercial launch of Evolysse™ Form and Evolysse™ Smooth in 2025 will be followed by Evolysse™ Sculpt in 2026, and Evolysse™ Lips in 2027.
More About Avabello Aesthetics
Avabello is a premier luxury cosmetic wellness destination that seamlessly blends high-end aesthetic treatments with the highest standards of medical expertise. Located in Miami Beach , the practice offers a holistic approach to beauty and wellness, featuring cutting-edge non-invasive and minimally invasive treatments delivered in a sophisticated, spa-like environment.
Distinguished by its direct oversight from renowned board-certified plastic surgeon Benjamin Eskenazi , MD, FACS, Avabello elevates every treatment with medical precision, personalized care, and a commitment to enhancing natural beauty. Dr. Eskenazi is a graduate of the prestigious Emory University School of Medicine who initially pursued heart surgery before discovering his passion for plastic surgery during his residency at UT Southwestern.
Dr. Eskenazi is dual board-certified by the American Board of Surgery and the American Board of Plastic Surgery, and serves as a featured speaker at national aesthetic medicine conferences. He is a Fellow of the American College of Surgeons, and a Member of the American Society of Plastic Surgeons and American Society of Aesthetic Plastic Surgeons. His dedication to innovation, precision, and patient satisfaction has earned him recognition as one of the country's leading plastic surgeons.
Media Contact
Isabella Franco
Avabello Aesthetics
(305) 798-4656
info@avabello.com
https://www.avabello.com
SOURCE Avabello Aesthetics
FAQ**
How does Dr. Benjamin Eskenazi's expertise in facial anatomy and injectable treatments enhance the rollout of Evolus Inc. EOLS's new Evolysse™ filler line?
What specific responsibilities will Dr. Eskenazi have as lead consultant for the Evolus Inc. EOLS Evolysse™ filler launch, and how will he support aesthetic providers?
How does the groundbreaking Cold-X™ technology in Evolus Inc. EOLS's Evolysse™ fillers compare to previous hyaluronic acid dermal fillers in terms of safety and efficacy?
In what ways does Dr. Eskenazi’s partnership with Evolus Inc. EOLS reflect the company's commitment to patient safety and provider education?
**MWN-AI FAQ is based on asking OpenAI questions about Evolus Inc. (NASDAQ: EOLS).
NASDAQ: EOLS
EOLS Trading
-2.42% G/L:
$5.24 Last:
197,327 Volume:
$5.30 Open:
